Symbols / ALMS $26.26 +0.23%
ALMS Chart
About
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.27B |
| Enterprise Value | 2.40B | Income | -245.15M | Sales | 22.12M |
| Book/sh | 3.69 | Cash/sh | 3.62 | Dividend Yield | — |
| Payout | 0.00% | Employees | 221 | IPO | — |
| P/E | — | Forward P/E | -8.22 | PEG | — |
| P/S | 148.02 | P/B | 7.12 | P/C | — |
| EV/EBITDA | -5.45 | EV/Sales | 108.28 | Quick Ratio | 5.83 |
| Current Ratio | 6.01 | Debt/Eq | 9.82 | LT Debt/Eq | — |
| EPS (ttm) | -2.15 | EPS next Y | -3.19 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-25 | ROA | -61.46% |
| ROE | -66.88% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -53.72% | Profit Margin | 0.00% | Shs Outstand | 117.51M |
| Shs Float | 66.27M | Short Float | 15.90% | Short Ratio | 5.70 |
| Short Interest | — | 52W High | 30.60 | 52W Low | 2.76 |
| Beta | — | Avg Volume | 2.99M | Volume | 746.33K |
| Target Price | $38.80 | Recom | Strong_buy | Prev Close | $26.20 |
| Price | $26.26 | Change | 0.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$38.80
Mean price target
2. Current target
$26.21
Latest analyst target
3. DCF / Fair value
$-29.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.21
Low
$32.00
High
$50.00
Mean
$38.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | init | Raymond James | — → Strong Buy | $46 |
| 2026-02-25 | init | Stifel | — → Buy | $44 |
| 2026-01-21 | init | Chardan Capital | — → Buy | $37 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-01-07 | main | Leerink Partners | Outperform → Outperform | $32 |
| 2026-01-07 | main | Morgan Stanley | Overweight → Overweight | $33 |
| 2026-01-07 | main | Guggenheim | Buy → Buy | $32 |
| 2026-01-06 | main | Wells Fargo | Overweight → Overweight | $39 |
| 2025-12-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-08-15 | main | Morgan Stanley | Overweight → Overweight | $22 |
| 2025-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-07-25 | init | Wells Fargo | — → Overweight | $17 |
| 2025-07-25 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-05-15 | main | Oppenheimer | Outperform → Outperform | $25 |
| 2025-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-04-22 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-20 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
- Alumis (NASDAQ:ALMS) Trading Down 3.5% - Here's What Happened - MarketBeat ue, 17 Mar 2026 18
- Biotech Alumis plans $175M stock sale in new public offering - Stock Titan ue, 06 Jan 2026 08
- Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026 - Meyka hu, 12 Mar 2026 06
- Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest - MarketBeat ue, 17 Mar 2026 08
- Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run - Yahoo Finance ue, 10 Mar 2026 22
- An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million - The Motley Fool Sat, 17 Jan 2026 08
- Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results - Quiver Quantitative ue, 13 Jan 2026 08
- Why Alumis Stock Spiked Almost 100% Yesterday - TIKR.com Wed, 07 Jan 2026 08
- Why Is ALMS Stock Rising Today? - Stocktwits ue, 06 Jan 2026 08
- Latham & Watkins Advises on Alumis’ Upsized US$345 Million Public Offering of Common Stock - Latham & Watkins LLP Fri, 09 Jan 2026 08
- Alumis Inc expected to post a loss of 98 cents a share - Earnings Preview - TradingView Fri, 13 Mar 2026 11
- Biopharma CEO to appear in live Leerink healthcare fireside chat - Stock Titan Mon, 02 Mar 2026 08
- Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise - Yahoo Finance Sun, 18 Jan 2026 08
- $ALMS stock is down 6% today. Here's what we see in our data. | ALMS Stock News - Quiver Quantitative Fri, 23 Jan 2026 08
- Alumis (NASDAQ:ALMS) Stock Price Down 6.7% - Should You Sell? - MarketBeat Wed, 11 Mar 2026 19
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 588235 | 9999995.0 | — | Purchase at price 17.00 per share. | AKKARAJU SRINIVAS | Director | — | 2026-01-09 00:00:00 | I |
| 1 | 411764 | 6999988.0 | — | Purchase at price 17.00 per share. | TANANBAUM JAMES B | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-08 00:00:00 | I |
| 2 | 411764 | 6999988.0 | — | Purchase at price 17.00 per share. | FORESITE CAPITAL MANAGEMENT VI, LLC. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-08 00:00:00 | I |
| 3 | 186377 | 1833760.0 | — | Purchase at price 8.95 - 10.73 per share. | AKKARAJU SRINIVAS | Director | — | 2025-12-05 00:00:00 | I |
| 4 | 262027 | 2039901.0 | — | Purchase at price 7.55 - 8.18 per share. | AKKARAJU SRINIVAS | Director | — | 2025-12-04 00:00:00 | I |
| 5 | 173589 | 1310677.0 | — | Purchase at price 7.46 - 7.64 per share. | AKKARAJU SRINIVAS | Director | — | 2025-12-01 00:00:00 | I |
| 6 | 72212 | 532925.0 | — | Purchase at price 7.38 per share. | TANANBAUM JAMES B | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-21 00:00:00 | I |
| 7 | 72212 | 532925.0 | — | Purchase at price 7.38 per share. | FORESITE CAPITAL MANAGEMENT VI, LLC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-21 00:00:00 | I |
| 8 | 125743 | 905350.0 | — | Purchase at price 7.20 per share. | AKKARAJU SRINIVAS | Director | — | 2025-11-20 00:00:00 | I |
| 9 | 241338 | 1529865.0 | — | Purchase at price 5.51 - 6.56 per share. | AKKARAJU SRINIVAS | Director | — | 2025-11-19 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -292.20M | -156.77M | -113.60M |
| TotalUnusualItems | -5.41M | -119.00K | |
| TotalUnusualItemsExcludingGoodwill | -5.41M | -119.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -294.23M | -154.99M | -111.93M |
| ReconciledDepreciation | 3.15M | 1.28M | 250.00K |
| EBITDA | -297.60M | -156.89M | -113.60M |
| EBIT | -300.75M | -158.17M | -113.85M |
| NetInterestIncome | 12.02M | 3.37M | 1.99M |
| InterestIncome | 12.02M | 3.37M | 1.99M |
| NormalizedIncome | -288.83M | -154.87M | -111.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -294.23M | -154.99M | -111.93M |
| TotalExpenses | 300.75M | 158.17M | 113.85M |
| TotalOperatingIncomeAsReported | -300.75M | -158.17M | -113.85M |
| DilutedAverageShares | 28.34M | 51.84M | 38.41M |
| BasicAverageShares | 28.34M | 51.84M | 38.41M |
| DilutedEPS | -10.38 | -2.99 | -2.91 |
| BasicEPS | -10.38 | -2.99 | -2.91 |
| DilutedNIAvailtoComStockholders | -294.23M | -154.99M | -111.93M |
| NetIncomeCommonStockholders | -294.23M | -154.99M | -111.93M |
| NetIncome | -294.23M | -154.99M | -111.93M |
| NetIncomeIncludingNoncontrollingInterests | -294.23M | -154.99M | -111.93M |
| NetIncomeContinuousOperations | -294.23M | -154.99M | -111.93M |
| PretaxIncome | -294.23M | -154.99M | -111.93M |
| OtherIncomeExpense | -5.50M | -187.00K | -72.00K |
| OtherNonOperatingIncomeExpenses | -93.00K | -68.00K | -72.00K |
| GainOnSaleOfSecurity | -5.41M | -119.00K | |
| NetNonOperatingInterestIncomeExpense | 12.02M | 3.37M | 1.99M |
| InterestIncomeNonOperating | 12.02M | 3.37M | 1.99M |
| OperatingIncome | -300.75M | -158.17M | -113.85M |
| OperatingExpense | 300.75M | 158.17M | 113.85M |
| ResearchAndDevelopment | 265.55M | 137.68M | 101.30M |
| SellingGeneralAndAdministration | 35.20M | 20.50M | 12.55M |
| GeneralAndAdministrativeExpense | 35.20M | 20.50M | 12.55M |
| OtherGandA | 35.20M | 20.50M | 12.55M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 54.41M | 51.84M | 51.84M |
| ShareIssued | 54.41M | 51.84M | 51.84M |
| TotalDebt | 30.72M | 32.58M | 1.78M |
| TangibleBookValue | 260.10M | -339.26M | -195.24M |
| InvestedCapital | 260.10M | -339.26M | -195.24M |
| WorkingCapital | 255.28M | 32.49M | 89.20M |
| NetTangibleAssets | 260.10M | -339.26M | -195.24M |
| CapitalLeaseObligations | 30.72M | 32.58M | 1.78M |
| CommonStockEquity | 260.10M | -339.26M | -195.24M |
| TotalCapitalization | 260.10M | -339.26M | -195.24M |
| TotalEquityGrossMinorityInterest | 260.10M | -339.26M | -195.24M |
| StockholdersEquity | 260.10M | -339.26M | -195.24M |
| GainsLossesNotAffectingRetainedEarnings | 40.00K | 2.00K | -127.00K |
| OtherEquityAdjustments | 40.00K | 2.00K | -127.00K |
| RetainedEarnings | -658.55M | -364.32M | -209.32M |
| AdditionalPaidInCapital | 918.61M | 25.05M | 14.21M |
| CapitalStock | 4.00K | 1.00K | 1.00K |
| CommonStock | 4.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 80.89M | 428.87M | 303.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 29.98M | 408.00M | 290.06M |
| OtherNonCurrentLiabilities | 814.00K | 1.77M | 4.12M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 375.37M | 285.47M |
| LongTermDebtAndCapitalLeaseObligation | 29.16M | 30.86M | 469.00K |
| LongTermCapitalLeaseObligation | 29.16M | 30.86M | 469.00K |
| CurrentLiabilities | 50.91M | 20.87M | 13.35M |
| CurrentDebtAndCapitalLeaseObligation | 1.56M | 1.72M | 1.31M |
| CurrentCapitalLeaseObligation | 1.56M | 1.72M | 1.31M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.76M | 5.58M | 3.58M |
| PayablesAndAccruedExpenses | 41.59M | 13.57M | 8.47M |
| CurrentAccruedExpenses | 31.96M | 12.45M | 6.75M |
| Payables | 9.62M | 1.12M | 1.72M |
| AccountsPayable | 9.62M | 1.12M | 1.72M |
| TotalAssets | 340.99M | 89.61M | 108.17M |
| TotalNonCurrentAssets | 34.80M | 36.26M | 5.61M |
| OtherNonCurrentAssets | 1.11M | 1.03M | 1.14M |
| NetPPE | 33.69M | 35.22M | 4.47M |
| AccumulatedDepreciation | -4.56M | -1.41M | -257.00K |
| GrossPPE | 38.25M | 36.63M | 4.73M |
| Leases | 17.62M | 17.59M | 31.00K |
| ConstructionInProgress | 0.00 | 578.00K | |
| OtherProperties | 17.95M | 16.36M | 3.59M |
| MachineryFurnitureEquipment | 2.68M | 2.68M | 529.00K |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 306.19M | 53.36M | 102.56M |
| OtherCurrentAssets | 762.00K | 95.00K | |
| RestrictedCash | 0.00 | 113.00K | 206.00K |
| PrepaidAssets | 15.35M | 3.48M | 8.98M |
| Receivables | 1.81M | 722.00K | 500.00K |
| TaxesReceivable | 1.11M | 614.00K | 500.00K |
| AccruedInterestReceivable | 698.00K | 108.00K | |
| CashCashEquivalentsAndShortTermInvestments | 288.26M | 48.95M | 92.86M |
| OtherShortTermInvestments | 118.74M | 2.96M | 67.25M |
| CashAndCashEquivalents | 169.53M | 46.00M | 25.61M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| FreeCashFlow | -256.81M | -134.47M | -110.13M |
| RepurchaseOfCapitalStock | 0.00 | ||
| IssuanceOfCapitalStock | 451.78M | 89.78M | 99.89M |
| CapitalExpenditure | -1.73M | -4.50M | -2.41M |
| EndCashPosition | 170.63M | 47.13M | 26.95M |
| BeginningCashPosition | 47.13M | 26.95M | 101.80M |
| ChangesInCash | 123.50M | 20.18M | -74.85M |
| FinancingCashFlow | 492.37M | 89.68M | 101.63M |
| CashFlowFromContinuingFinancingActivities | 492.37M | 89.68M | 101.63M |
| NetOtherFinancingCharges | 40.00M | -485.00K | |
| ProceedsFromStockOptionExercised | 590.00K | 389.00K | 1.73M |
| NetPreferredStockIssuance | 258.46M | 89.78M | 99.89M |
| PreferredStockIssuance | 258.46M | 89.78M | 99.89M |
| NetCommonStockIssuance | 193.32M | 0.00 | |
| CommonStockPayments | 0.00 | ||
| CommonStockIssuance | 193.32M | ||
| InvestingCashFlow | -113.79M | 60.47M | -68.75M |
| CashFlowFromContinuingInvestingActivities | -113.79M | 60.47M | -68.75M |
| NetInvestmentPurchaseAndSale | -112.06M | 64.97M | -66.34M |
| SaleOfInvestment | 128.00M | 76.25M | 142.73M |
| PurchaseOfInvestment | -240.06M | -11.28M | -209.07M |
| NetPPEPurchaseAndSale | -1.73M | -4.50M | -2.41M |
| PurchaseOfPPE | -1.73M | -4.50M | -2.41M |
| OperatingCashFlow | -255.08M | -129.97M | -107.72M |
| CashFlowFromContinuingOperatingActivities | -255.08M | -129.97M | -107.72M |
| ChangeInWorkingCapital | 14.76M | 12.06M | -1.92M |
| ChangeInOtherCurrentLiabilities | -1.86M | -144.00K | -820.00K |
| ChangeInPayablesAndAccruedExpense | 30.25M | 7.02M | 7.26M |
| ChangeInAccruedExpense | 21.75M | 7.66M | 5.96M |
| ChangeInPayable | 8.51M | -642.00K | 1.29M |
| ChangeInAccountPayable | 8.51M | -642.00K | 1.29M |
| ChangeInPrepaidAssets | -13.63M | 5.19M | -8.35M |
| OtherNonCashItems | 60.00K | 2.01M | 950.00K |
| StockBasedCompensation | 19.46M | 8.62M | 5.96M |
| AssetImpairmentCharge | 0.00 | 555.00K | 0.00 |
| AmortizationOfSecurities | -3.69M | -544.00K | -1.04M |
| DepreciationAmortizationDepletion | 3.15M | 1.28M | 250.00K |
| DepreciationAndAmortization | 3.15M | 1.28M | 250.00K |
| OperatingGainsLosses | 5.41M | 1.03M | |
| GainLossOnInvestmentSecurities | 5.41M | 119.00K | |
| GainLossOnSaleOfPPE | 5.00K | 911.00K | 0.00 |
| NetIncomeFromContinuingOperations | -294.23M | -154.99M | -111.93M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALMS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|